Bibliografia
Albright F, Bloomberg E, Smith PH (1940) Post-menopausal osteoporosis. Trans Assoc Am Physicians 55:298–305
Reifenstein EC, Albright F (1947) The metabolic effects of steroids in osteoporosis. J Clin Invest 26:24–56
Love RR, Mazess RB, Barden HS et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852–856
Harper MJ, Walpole AL (1966) Contrasting endocrine activities of cis and trans isomers in a series of substituted triphenylethylenes. Nature 212:87
Jaffe H, Bodansky A, Blair J (1932) The effects of parathormone and ammonium chloride on the bones of rabbits. J Exp Med 55:695–701
Selye H (1932) On the stimulation of new bone formation with parathyroid extract and irradiated ergosterol. Endocrinology 16:547–558
Albright P, Aub JC, Bauer W (1934) Hyperparathyroidism: a common and polymorphic condition as illustrated by seventeen proved cases from one clinic. JAMA 102:1276–1287
Reeve J, Tregear GW, Parsons JA (1976) Preliminary trial of low doses of human parathyroid hormone 1-34 peptide in treatment of osteoporosis. Calcif Tissue Res 21(Suppl):469–477
Milhaud G, Bloch-Michel H, Coutris G et al. (1969) Effect de la thyreocalcitonine de porc sur l’osteoporose humaine. C R Acad Sci (D) 268(part 3):3100–3102
Fleisch H, Bisaz S (1962) Isolation from urine of pyrophosphate, a calcification inhibitor. Am J Physiol 203:671–675
Fleisch H, Russell RGG, Straumann F (1966) Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis. Nature 212:901–903
Fleisch H, Maerki J, Russell RG (1966) Effect of pyrophosphate on dissolution of hydroxyapatite and its possible importance in calcium homeostasis. Proc Soc Exp Biol Med 122:317–320
Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep ML et al. (1986) Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1:27–39
Simonet WS, Lacey DL, Dunstan CR et al. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89:309–319
Lacey DL, Timms E, Tan HL et al. (1998) Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93:165–176
Atkinson JE, Cranmer P, Mohr S et al. (2003) Bone mineral density is increased following monthly administration of AMG 162 in cynomologus monkeys. J Bone Miner Res 18:S92
Bekker PJ, Holloway DL, Rasmussen AS et al. (2004) A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women. J Bone Miner Res 19:1059–1066
Swanson LW, Mogenson GJ (1981) Neural mechanisms for the functional coupling of autonomic, endocrine and somatomotor reponses in adaptative behavior. Brains Res Rev 3:1–34
Toni R, Di Conza G, Barbaro F et al. (2020) Microtopography of immune cells in osteoporosis and bone lesions by endocrine disruptors. Front Immunol 11:1737
Huxley-Jones J, Foord SM, Barnes MR (2008) Drug discovery in the extracellular matrix. Drug Discov Today 13:685–694
Ringraziamenti
Questo studio è stato sviluppato nell’ambito delle convenzioni 2018–2023 tra DIMEC UNIPR e Centro Medico Galliera, San Venanzio (BO), ratifiche 27/06/2018 e 08/10/2020, Progetto Qualità diagnostico-terapeutica ambulatoriale e linee guida nazionali ed internazionali per le malattie endocrino-metaboliche. Parte di questi dati contribuiscono al materiale didattico on-line per l’insegnamento di Medicina Rigenerativa in Endocrinologia, Corso di Laurea Magistrale in Biotecnologie Mediche, Veterinarie e Farmaceutiche dell’Università di Parma, accessibile al portale dell’insegnamento sulla piattaforma Elly – UNIPR.
Author information
Authors and Affiliations
Corresponding author
Additional information
Nota della casa editrice
Springer Nature rimane neutrale in riguardo alle rivendicazioni giurisdizionali nelle mappe pubblicate e nelle affiliazioni istituzionali.
Presentato il 18 gennaio 2020 nell’ambito dell’evento nazionale ECM “Osteoporosi: novità e prospettive”, tenutosi con i Patrocini SIE e IRCCS Istituto Ortopedico Rizzoli, Bologna presso l’Unità OSTEONET (Osteoporosi, Nutrizione, Endocrinologia e Terapie Innovative), del CMG - DIMEC UNIPR, San Venanzio di Galliera (BO).
Rights and permissions
About this article
Cite this article
Toni, R., Borghi, D., Quarantini, E. et al. Denosumab e cambio di paradigma nella terapia dell’osteoporosi. L'Endocrinologo 22, 253–257 (2021). https://doi.org/10.1007/s40619-021-00869-6
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40619-021-00869-6